Varenicline effects on cocaine self administration and reinstatement behavior.
This study tested the effects of the nicotine addiction treatment varenicline on cocaine self administration (SA) and reinstatement. In one SA experiment, rats were trained to self-administer cocaine (0.75 mg/kg/infusion). Thereafter, daily SA sessions continued as before except that every fourth session was preceded by a presession injection of varenicline (0.0, 0.3, 1.0 and 2.0 mg/kg, SC, 50-min presession). In three reinstatement experiments, animals were exposed sequentially to SA training, extinction training, and several reinstatement test sessions. In two of the reinstatement experiments, cocaine-seeking was reinstated by presentation of cocaine-predictive cues at the onset of the test session (cue reinstatement). In a third reinstatement experiment, cocaine-seeking was reinstated by a presession injection of cocaine (drug reinstatement). Each reinstatement session was preceded by an injection of either vehicle or varenicline (dose range of 0.1-2.0 mg/kg). The SA and reinstatement experiments showed that low-dose varenicline decreases reinstatement behavior, without significantly affecting cocaine SA. In contrast, high-dose varenicline increases reinstatement of cocaine-directed behavior and decreases cocaine SA. A control study showed that sucrose-directed behavior is unaltered by varenicline. On the basis of these findings, low-varenicline doses might decrease relapse in cocaine-addicted individuals, but high doses of varenicline might have the opposite effect.
Guillem
Karine
K
Department of Integrative Neurophysiology, CNCR, VU University, Amsterdam, The Netherlands.
Peoples
Laura L
LL
D000818:Animals; D016739:Behavior, Addictive / Q000188:drug therapy*; D001552:Benzazepines / Q000627:therapeutic use*; D003042:Cocaine / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D003216:Conditioning, Operant / Q000187:drug effects; D003463:Cues; D005108:Extinction, Psychological / Q000187:drug effects; D008297:Male; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D011810:Quinoxalines / Q000627:therapeutic use*; D051381:Rats; D020318:Rats, Long-Evans; D055502:Secondary Prevention; D012646:Self Administration; D000068580:Varenicline
D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D003042:Cocaine; D000068580:Varenicline